ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, Rafique A, Potocky TB, Shan J, Delfino FJ, Shi E, Huang T, Martin JH, Chen G, Macdonald D, Rudge JS, Thurston G, Daly C.
Zhang L, et al. Among authors: castanaro c.
Mol Cancer Ther. 2014 May;13(5):1345-55. doi: 10.1158/1535-7163.MCT-13-1033. Epub 2014 Mar 14.
Mol Cancer Ther. 2014.
PMID: 24634416